Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases

Stopped Due to insufficient recruitment, the clinical trial was terminated prematurely

Conditions

• Malignant Melanoma Stage IV
• BRAF V600 Mutation
• Brain Metastases

Interventions

• DRUG: Vemurafenib
• DRUG: Cobimetinib

Sponsor

Technische Universität Dresden